Jonathan Norris, managing director at Silicon Valley Bank, points to increased fund-raising by healthcare-focused venture capital firms and a surge by strategic investors in Series A deals as strong signs for the sector. Ophthalmology biopharma start-ups may be seeing a slowdown in venture investing, but early-stage device companies are going strong. Norris also presents an interesting observation about the returns generated by investments in PMA-focused medical devices.
STAY UP TO DATE WITH OIS
Get the Latest News, Podcasts and Videos.